Awards & Milestones

Awards & milestones

Recognition for innovation, clinical translation and commercialization

From academic spin-off to AI SaMD commercialization, AItewan's technology and platform have earned national awards and industry recognition, and showcase the Liger platform and DeepBT® brain-tumor AI at exhibitions at home and abroad.

  • National Innovation Award
  • Smart Innovation finalist
  • InnoVEX 2026
Awards & Recognition

Awards & recognition

Each award reflects a distinct kind of value

National Innovation Award · Academia Spin-off + Elite Award
2023

National Innovation Award · Academia Spin-off + Elite Award

Institute for Biotechnology and Medicine Industry (19th)

Recognizes the translation of academic research into a startup product, and the company's sustained advancement and commercialization capability.

Taiwan Innotech Expo · LITEON Special Award + Silver Medal
2024

Taiwan Innotech Expo · LITEON Special Award + Silver Medal

MOEA / LITEON

Technical innovation recognized by an industry leader, signalling the commercialization potential of brain-tumor AI in medical imaging.

Smart Innovation Award · Precision-Health Finalist
2025

Smart Innovation Award · Precision-Health Finalist

MOEA

Acknowledges the applied value of the Liger platform and DeepBT® in AI precision health and real-world medical imaging.

Future Tech Award · Precision Health

National Science and Technology Council

Recognizes frontier AI medical-imaging technology and its clinical-translation potential.

Milestones

Company milestones

Regulatory, product and recognition timeline

  1. 2023

    Recognized with the 19th National Innovation Award (academia spin-off) and the National Innovation Elite Award

  2. 2023.07

    DeepBT® Detector AI brain-tumor detection system received TFDA Class II clearance (No. 007906)

  3. 2023.08

    Obtained medical-device distribution and manufacturing licenses (QMS2129)

  4. 2024

    Received the Silver Medal and LITEON Special Award at the 2024 Taiwan Innotech Expo

  5. 2025

    Liger MedAI Platform received TFDA Class II clearance (No. 008624); DeepBT® Detector Plus cleared by TFDA (No. 008460); finalist of the 2025 Smart Innovation Award

  6. 2026.04

    DeepBT® Detector Plus received U.S. FDA 510(k) clearance (K252190, Substantially Equivalent)

  7. 2026

    DeepBT® Detector A+ (3rd generation, five tumor types) under TFDA review; exhibited at InnoVEX 2026

Events & Exhibitions

Events & exhibitions

InnoVEX 2026, Smart Innovation Award exhibition and more

We showcase the Liger platform and DeepBT® brain-tumor AI at exhibitions, engaging clinical, industry and investment partners.

Contact AItewan

Want to explore collaboration or deployment?

Reach out about hospital deployment, research collaboration, or investment and business partnerships.